Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study.
Hannah BowerThomas FrisellDaniela Di GiuseppeBénédicte DelcoigneGerd-Marie AhleniusEva BaecklundKaterina ChatzidionysiouNils FelteliusHelena Forsblad-d'EliaAlf KastbomLars KlareskogElisabet LindqvistUlf LindströmCarl TuressonChristopher SjöwallJohan Asklingnull nullPublished in: Annals of the rheumatic diseases (2021)
Risks of severe COVID-19-related outcomes were increased among patients with IJDs, but risk increases were also seen for non-COVID-19 morbidity. Overall absolute and excess risks are low and the level of risk increases are largely proportionate to those in the general population, and explained by comorbidities. With possible exceptions, antirheumatic drugs do not have a major impact on these risks.